Biosimilars in China: the price war that’s good for patients
Herceptin, Rituxan, Avastin — these blockbuster antibodies cost a fortune. But in China, biosimilars are slashing prices by 70‑80%, making cancer treatment accessible to the middle class. The China antibodies market research shows that the biosimilar segment is growing twice as fast as innovator antibodies, thanks to government policies that prioritize local manufacturing....
0 Compartilhamentos
95 Visualizações